Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

G Pryce, Zubair Ahmed, DJR Hankey, SJ Jackson, JL Croxford, JM Pocock, C Ledent, A Petzold, AJ Thompson, G Giovannoni, ML Cuzner, D Baker

    Research output: Contribution to journalArticle

    294 Citations (Scopus)


    Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
    Original languageEnglish
    Pages (from-to)2191-2202
    Number of pages12
    Publication statusPublished - 23 Jun 2003


    Dive into the research topics of 'Cannabinoids inhibit neurodegeneration in models of multiple sclerosis'. Together they form a unique fingerprint.

    Cite this